More than APIs, Indian pharma industry needs to reduce dependency on drug intermediates: Premchand Godha Read more
DoP to finalise guidelines to select locations of three bulk drug parks and four med devices parks: Gowda Read more
Local API production in India for COVID-19 repurposed drugs may offer competitive advantage: GlobalData Read more